Development and evaluation of insulin-loaded cationic solid lipid nanoparticles for oral delivery

Hecq, Julien; Amighi, Karim; Goole, Jonathan

doi:10.1016/j.jddst.2016.10.012

Cited by 37 publications

(15 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is likely that the combination or synergistic action of all these effects is the cause of the large increase in oral BA associated with lipid nanovehicles and, in turn, of the increasing trend in the selection of this route of administration for SLN/NLC (see Figure 4). Furthermore, due to all the previously described effects, lipid-based NP have been examined for the oral delivery of peptide therapeutics, such as salmon calcitonin (Chen et al, 2013;Fan et al, 2014) and insulin (Hecq et al, 2016;Xu et al, 2018;Alsulays et al, 2019).…”

Section: Oral Routementioning

confidence: 99%

Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects

Montoto

Muraca

Ruiz

2020

Front. Mol. Biosci.

335

148

View full text Add to dashboard Cite

Section: Oral Routementioning

confidence: 99%

Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects

Montoto

Muraca

Ruiz

2020

Front. Mol. Biosci.

335

148

View full text Add to dashboard Cite

“…Hence, various nanocarrier systems have been extensively investigated in oral delivery of biologics including PPs, vaccines and nucleic acids. According to materials of nanocarriers, there are primarily three categories of nanoparticles, such as polymeric, lipid-based and inorganic nanoparticles, some of which have demonstrated good delivery effect for PPs by oral routes ( Table 4 106 , 120 , 217 , 219 , 225 , 290 , 291 , 292 , 293 , 294 , 295 , 296 , 297 , 298 , 299 , 300 , 301 , 302 , 303 , 304 , 305 , 306 , 307 , 308 , 309 , 310 , 311 ).…”

Section: Current Strategies Towards Enhancement Of the Oral Absorption Of Ppsmentioning

confidence: 99%

Oral delivery of proteins and peptides: Challenges, status quo and future perspectives

Zhu

Chen

Paul

et al. 2021

Acta Pharmaceutica Sinica B

153

View full text Add to dashboard Cite

Proteins and peptides (PPs) have gradually become more attractive therapeutic molecules than small molecular drugs due to their high selectivity and efficacy, but fewer side effects. Owing to the poor stability and limited permeability through gastrointestinal (GI) tract and epithelia, the therapeutic PPs are usually administered by parenteral route. Given the big demand for oral administration in clinical use, a variety of researches focused on developing new technologies to overcome GI barriers of PPs, such as enteric coating, enzyme inhibitors, permeation enhancers, nanoparticles, as well as intestinal microdevices. Some new technologies have been developed under clinical trials and even on the market. This review summarizes the history, the physiological barriers and the overcoming approaches, current clinical and preclinical technologies, and future prospects of oral delivery of PPs.

show abstract

“…However, the hydrophobic nature of SLPs limits its encapsulation of hydrophilic peptides accounting for low EE. Hecq et al 102 dissolved Ins into the inner aqueous phase and then emulsified in an organic phase to prepare a bioadhesive cationic SLPs, which increased 2.5-fold the transshipment of capped Ins through co-cultured Caco-2/HT29 cells compared to free Ins. Boushra et al 103 adopted three different hydrophilic viscosity-enhancing agents (VAs): propylene glycol (PG), PEG 400 and PEG 600 within SLP cores to develop Ins-loaded NCs with enhanced viscosity.…”

Section: Lipid-based Particlesmentioning

confidence: 99%

Multifunctional oral delivery systems for enhanced bioavailability of therapeutic peptides/proteins

Han

Gao

Chen

et al. 2019

Acta Pharmaceutica Sinica B

102

View full text Add to dashboard Cite

In last few years, therapeutic peptides/proteins are rapidly growing in drug market considering their higher efficiency and lower toxicity than chemical drugs. However, the administration of therapeutic peptides/proteins is mainly limited in parenteral approach. Oral therapy which was hampered by harsh gastrointestinal environment and poorly penetrating epithelial barriers often results in low bioavailability (less than 1%–2%). Therefore, delivery systems that are rationally designed to overcome these challenges in gastrointestinal tract and ameliorate the oral bioavailability of therapeutic peptides/proteins are seriously promising. In this review, we summarized various multifunctional delivery systems, including lipid-based particles, polysaccharide-based particles, inorganic particles, and synthetic multifunctional particles that achieved effective oral delivery of therapeutic peptides/proteins.

show abstract

Development and evaluation of insulin-loaded cationic solid lipid nanoparticles for oral delivery

Cited by 37 publications

References 58 publications

Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects

Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects

Oral delivery of proteins and peptides: Challenges, status quo and future perspectives

Multifunctional oral delivery systems for enhanced bioavailability of therapeutic peptides/proteins

Contact Info

Product

Resources

About